DNLI: Options Skew Builds as Short Sellers Pare Back

Denali Therapeutics reports Q3 results on November 5 with an unusual split in its positioning data: options traders are more defensive than they have been all year, while the short-selling crowd has quietly reduced exposure over the past month.

The options signal is the clearest tension heading into the print. The put/call ratio has climbed to 1.58, more than 1.5 standard deviations above its 20-day average of 1.43, with the ratio drifting higher every session over the past two weeks. That is consistent with investors paying up for downside protection ahead of a binary biotech catalyst, though the ratio remains well below its 52-week peak of 2.41, so the skew is elevated but not panicked. The stock itself closed at $19.45 on November 3, up 3.1% on the day and roughly 1.2% on the week, a solid relative performance against a median peer decline of around 4%.

Short interest tells the opposite story. Bears have trimmed positions by more than 9% over the past month, bringing short interest to roughly 10.3% of the free float, still a material level for a mid-cap biotech but moving in the wrong direction for committed bears. The borrow market is not adding any pressure: availability is exceptionally loose at 1,544%, meaning there are roughly 15 shares available to lend for every one already borrowed, and the cost to borrow a low 0.49%. Taken together, the lending market puts no structural squeeze pressure on short sellers who want to hold or add to their positions.

The debate among analysts is essentially a question of whether Denali's accelerated regulatory pathway for AVLAYAH translates into durable commercial traction. The bull case rests on the early patient dosing, the biomarker response that the company says exceeds standard of care, a $1.05 billion cash position exiting Q1, and Takeda's exit leaving Denali with full commercial economics. Morgan Stanley, Deutsche Bank, UBS, and B. Riley Securities all raised price targets in the months following the last print, with a consensus mean near $35.50 against a current price of $19.45. The bear case is regulatory: accelerated approvals can be reversed or conditioned on further data, and the label as written may limit addressable market. Financing risk is also live: the company is loss-making, with a price-to-earnings ratio deep in negative territory, and will likely need additional capital to fund the full pipeline.

T. Rowe Price is the standout institutional development in the ownership picture. The firm filed a 13G/A in July showing its stake had nearly doubled from 5.4% to 10.2% of the class, making it by far the largest disclosed holder at roughly 12% of shares as reported at the end of September. That is a material conviction bet from a large fundamental manager, in contrast to FMR, which trimmed from 5.8% to 4.2% over a similar timeframe. All 13D/G positions are as last disclosed around the 5% threshold and may not reflect current holdings.

The November 5 print will test whether AVLAYAH's early commercial metrics, specifically patient uptake pace and biomarker response durability, justify the significant premium the consensus still embeds over the current share price.